Biogen looks to expand neuro pipeline via C4, Skyhawk deals
- maura169
- Jan 4, 2019
- 1 min read
A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.)
For more information visit:
SKYHAWK MEDIA CONTACT:
Maura McCarthy
Comments